Anti-TL1A treatment targets TL1A (Tumor Necrosis Factor-like ligand 1A), which regulates mucosal defense in the intestines, and therefore inflammation, and is involved in the pathogenesis of IBD [120]. Here, TNFSF15 is linked to inflammatory bowel disease.